This is the authors' abstract. We don't add key points for this paper.
Introduction Interleukin-1 (IL-1) inhibitors are widely used in autoinflammatory diseases (AID) such as Still’s disease and monogenic inflammasomopathies, including cryopyrinopathies (CAPS) and familial Mediterranean fever. As these conditions frequently affect women of reproductive age and data are limited, concerns remain regarding anti-IL-1 therapy safety during pregnancy. We aimed to evaluate maternal and neonatal outcomes in women exposed to anti-IL-1 therapy during conception and pregnancy.Methods This prospective observational study included pregnant women from the Groupe de recherche sur la Grossesse et les Maladies Rares (GR2) prospective cohort, spanning 76 French centres before September 2024. Women exposed to anti-IL-1 therapy during conception or pregnancy were selected. Maternal and obstetrical outcomes were compared with a 1:1 matched control group of unexposed women with similar conditions and with the nationwide 2021 French National Perinatal Survey.Results Thirty-four pregnancies (three twin pregnancies) in 31 women were exposed to anakinra (n=30) and/or canakinumab (n=5) for Still’s disease (n=15), familial Mediterranean fever (n=15), CAPS (n=3), undifferentiated systemic AID (n=2), tumour necrosis factor receptor-associated periodic syndrome and recurrent pericarditis (n=1 each). Reported outcomes included infections (n=6), intrahepatic cholestasis (n=3), gestational diabetes (n=2), gestational hypertension (n=1) and intrauterine growth restriction (n=1). Median gestational age was 39 weeks with five preterm births between 32 and 37. One baby was diagnosed with laryngomalacia but did not require surgery. Paediatric follow-up (33 babies to 6 months, 30 thereafter for a median of 14.5 months (13–24)) confirmed normal infant development. Maternal and obstetrical outcomes did not differ between treated with anti-IL-1 and untreated with anti-IL-1 patients with AID.Conclusion Anti-IL-1 therapy, particularly anakinra, appears safe during pregnancy in women with systemic AID.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Delplanque et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: